Shares of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) reached a new 52-week high on Wednesday . The company traded as high as $9.40 and last traded at $8.26, with a volume of 138000 shares trading hands. The stock had previously closed at $7.95.
A number of research firms have recently weighed in on DRNA. ValuEngine lowered Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Zacks Investment Research lowered Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. HC Wainwright restated a “buy” rating and set a $10.00 target price (up previously from $6.00) on shares of Dicerna Pharmaceuticals in a report on Friday, November 3rd. Finally, Chardan Capital restated a “hold” rating on shares of Dicerna Pharmaceuticals in a report on Monday, August 14th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $6.81.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.22). The business had revenue of $0.47 million for the quarter. Dicerna Pharmaceuticals had a negative net margin of 5,895.26% and a negative return on equity of 293.25%. The firm’s quarterly revenue was up 192.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.68) EPS. sell-side analysts expect that Dicerna Pharmaceuticals, Inc. will post -3.04 EPS for the current year.
Institutional investors have recently made changes to their positions in the stock. Deschutes Portfolio Strategy LLC bought a new position in shares of Dicerna Pharmaceuticals during the third quarter valued at approximately $575,000. Palo Alto Investors LLC raised its holdings in Dicerna Pharmaceuticals by 4.0% in the second quarter. Palo Alto Investors LLC now owns 500,913 shares of the biopharmaceutical company’s stock worth $1,588,000 after purchasing an additional 19,394 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Dicerna Pharmaceuticals by 2.4% in the first quarter. Renaissance Technologies LLC now owns 418,500 shares of the biopharmaceutical company’s stock worth $1,423,000 after purchasing an additional 9,818 shares in the last quarter. EcoR1 Capital LLC raised its holdings in Dicerna Pharmaceuticals by 101.0% in the second quarter. EcoR1 Capital LLC now owns 767,992 shares of the biopharmaceutical company’s stock worth $2,435,000 after purchasing an additional 385,992 shares in the last quarter. Finally, UBS Group AG raised its holdings in Dicerna Pharmaceuticals by 0.6% in the first quarter. UBS Group AG now owns 284,645 shares of the biopharmaceutical company’s stock worth $968,000 after purchasing an additional 1,599 shares in the last quarter. Institutional investors own 56.03% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://sportsperspectives.com/2017/11/17/dicerna-pharmaceuticals-inc-drna-sets-new-52-week-high-at-9-40.html.
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Receive News & Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.